IO Biotech Inc. Common Stock

IO Biotech Inc. a clinical-stage biopharmaceutical company develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate IO102-IO103 which is designed to target immunosuppressive proteins such as Indoleamine 23-dehydrogenase (IDO) and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma as well as in phase 1 clinical trial to treat lung head and neck bladder and melanoma cancer. It also develops IO112 a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen Denmark.